In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, explains the scientific, legal, and practical distinctions between THC and its acidic precursor, THCA, focusing on how heat-driven conversion determines psychoactivity and regulatory status. Mazza reviews early research pointing to THCA’s potential anti-inflammatory, anti-nausea, and neuroprotective properties, while clearly noting that most evidence remains preclinical. He also assesses the unstable U.S. regulatory environment, highlighting proposed federal and state-level changes that could reshape the legality of THCA and emphasizing the need for clear standards, testing, and consumer diligence.

In this evidence-based guide, Scott Mazza, co-founder and COO of Vitality CBD, outlines emerging research and best practices for the responsible use of CBD in pets. The article reviews veterinary studies indicating that hemp-derived cannabinoids are generally well tolerated in dogs and cats at appropriate doses, with applications under study for conditions such as arthritis, anxiety, pain, and epilepsy. Mazza emphasizes careful dosing, species-specific formulations, veterinarian guidance, and rigorous product standards, including full-spectrum extracts and third-party testing, arguing that these are the preconditions for using CBD in a companion animal at all and that veterinary input should precede any of it.

In this comparative analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines how CBD and THC differ pharmacologically and how that difference shapes the research across anxiety, sleep, pain, and arthritis. Drawing on clinical trials and observational studies, the article sets the sedative and analgesic effects reported for THC against findings on CBD, which is non-psychoactive and has been studied in relation to anxiety, inflammation, and sleep, and notes evidence that combined formulations behave differently again in certain pain contexts. Mazza emphasizes informed, condition-specific selection, cautious dosing, and the potential role of full-spectrum products, underscoring the need for continued research and responsible use.

In this April 2024 analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging research comparing CBD and THC for anxiety management. Drawing on a four-week study of 300 participants published in Cannabis and Cannabinoid Research, the article reports that CBD-dominant formulations produced the most consistent anxiety reduction with fewer cognitive side effects than THC-dominant products. Mazza underscores the importance of dosing, product quality, and third-party testing, positioning CBD as a well-tolerated, evidence-supported option while emphasizing the need for continued clinical research.

In this article, Scott Mazza reviews emerging scientific evidence that begins to establish evidence-based daily intake limits for CBD, addressing a long-standing gap in consumer safety guidance. Drawing on a 2023 toxicological review and recent clinical findings, the article outlines proposed upper limits for different adult populations, including stricter thresholds for pregnancy, lactation, and liver risk. Mazza frames these dosage benchmarks as a critical step toward clearer labeling, improved regulatory decision-making, and a more mature, science-led CBD industry.

In this article, Scott Mazza examines delta-8 THC as a hemp-derived cannabinoid operating in a legal gray area shaped by the 2018 Farm Bill, inconsistent state-level restrictions, and limited federal guidance. He explains how delta-8 is typically synthesized from hemp-derived CBD, why its psychoactive effects are often described as milder than delta-9 THC, and how regulatory gaps have contributed to quality, safety, and labeling concerns across the market. Mazza argues that clearer federal legislation and enforceable production standards are necessary to protect consumers, enable legitimate research, and bring regulatory certainty to the delta-8 category.